Aims/hypothesis Impairment of beta cell mass and function is evident in both type 1 and type 2 diabetes. In healthy physiological conditions pancreatic beta cells adapt to the body's increasing insulin requirements by proliferation and improved function. We hypothesised that during the development of diabetes, there is an increase in the expression of inhibitory factors that prevent the beta cells from adapting to the increased need for insulin. We evaluated the effects of bone morphogenetic protein (BMP) 2 and -4 on beta cells. Methods The effects of BMP2 and -4 on beta cell proliferation, apoptosis, gene expression and insulin release were studied in isolated islets of Langerhans from rats, mice and humans. The expression of BMPs was analysed by immunocytochemistry and real-time PCR. The role of endogenous BMP was investigated using a soluble and neutralising form of the BMP receptor 1A.
Introduction
Deficiency in functional beta cell mass is a hallmark of both type 1 and type 2 diabetes. Current treatments generally focus on increasing insulin secretion, replacing insulin or improving insulin sensitivity. Although very effective, none of these options are curative. Therefore, a major goal is to identify factors that are capable of restoring beta cell mass and function. In the adult organism, new beta cells can be generated by replication of already existing beta cells, from adult stem/progenitor cells through induction of differentiation or by trans-differentiation of other islet cells [1] .
The ability of beta cells to undergo mitosis has been demonstrated in rodents [2] [3] [4] . In response to insulin resistance, beta cells proliferate significantly to compensate for the increased demand for insulin [5, 6] . Several growth factors and pathways, which can induce rodent beta cell proliferation, have been identified [7] [8] [9] [10] [11] . In vitro, it has been shown that rodent beta cells can proliferate in response to various growth factors and the effects of these factors seem to be direct and involve classical mitotic signalling and stimulation of entry of cells into the cell cycle [12] .
Compared with rodent beta cells, human beta cells appear to have a low replication potential. Human beta cells do retain some capacity to expand in number, since beta cell mass is increased during pregnancy [13] and obesity [14] .
In order to improve our understanding of the factors and mechanisms involved in the regulation of beta cell replication and function, it is important to search for novel factors and to study their possible interactions with known beta cell growth inducers. Another strategy is to investigate why beta cells are so resistant to growth factors, which may be linked to the presence of growth inhibitors rather than lack of growth promoters.
The bone morphogenetic proteins (BMPs) belong to the TGF-β superfamily of growth and differentiation factors. The two highly identical members BMP2 and -4 interact with the BMP type I receptors, activin-like kinase (ALK)-3 and -6, which form complexes with the BMP type II receptor and phosphorylate SMAD-1/5/8 mediating the effects of BMP2 and -4 [15] .
Very little is known about the potential role of BMPs in diabetes. In animal models of both type 1 and type 2 diabetes, BMP2 and -4 mRNA and protein are upregulated in the vasculature [16] [17] [18] [19] , while no information exists concerning regulated expression of BMPs in islets during the progression of diabetes in humans. However, BMP2 and -4 are expressed in islets [20] [21] [22] and BMP2 mRNA is upregulated in response to pro-inflammatory cytokines in human and rodent islets [23, 24] . Whereas important roles for BMP2 and -4 in pancreas and beta cell development are well established [25] [26] [27] , little information about the effects of these factors on differentiated beta cells exists. Deletion of Bmpr1a in vivo has indicated that BMP4 is essential for beta cell function [21, 28] , while pharmacological inhibition of BMP activity improves glycaemic control in db/db mice [17] . Deletion of a central BMP target gene Id1 also improves glucose metabolism [29] , suggesting a complex role of BMPs in glucose homeostasis and islet function.
Methods
Islet isolation and culture Rat and mouse islets were isolated as described in [30] and [31] , respectively. db/db and db/+ mice were obtained from Taconic, Lille Skensved, Denmark. Experiments involving animals were approved by the local ethics committee. Human islets were provided through the JDRF Islet Distribution Program. The culture time for islets before stimulation was 5-7 days for rat and human islets and 1 day for mouse islets. Islets were cultured in RPMI1640 medium supplemented with 2% human serum (Lonza, Basel, Switzerland), or dispersed into single cells using 0.2% trypsin, 10 mmol/l EDTA (Gibco BRL, Grand Island, NY, USA) in 1× Hanks' balanced salt solution (rat) or by digestion with Accutase (human; PAA Laboratories GmbH, Colbe, Germany), as described previously [32] .
Dispersed islet cells were plated on coverslips coated with extracellular matrix (ECM; Biological Industries, Kibbutz Beit Haemek, Israel) in medium supplemented with 2% human serum.
Growth factors and reagents
The following reagents were used in this study: BMP2 and BMP4 (R&D Systems Europe, Oxford, UK); human growth hormone (GH) and liraglutide (Novo Nordisk, Bagsvaerd, Denmark); and recombinant human BMPR-IA/ALK-3/Fc and BMPR-IB/ALK-6/Fc receptor fusion proteins (R&D Systems).
Proliferation assay Beta cell proliferation was measured in islet cells or intact islets cultured on ECM by 10 μmol/l 5-ethynyl-2'-deoxyuridine (EdU; Invitrogen, Paisley, UK) added 24 h prior to fixation. Proliferating beta cells were detected by EdU incorporation with Click-iT EdU Cell Proliferation Assay (Invitrogen), followed by staining for insulin or pancreatic and duodenal homeobox 1 (PDX1). A minimum of 1,000 cells were counted per experiment in each condition.
Apoptosis assays Apoptosis was measured in intact islets using the Cell Death Detection Assay (Roche Diagnostics, Basel, Switzerland). Caspase 3/7 activity was measured in islet extracts by the Apo-ONE Caspase3/7 Assay (Promega, Madison, WI, USA).
Western blotting Western blotting was performed as described previously [33] .
Antibodies and immune staining The following antibodies were used in our experiments: guinea pig anti-insulin, rabbit anti-BMP2, rabbit anti-BMP4 (Abcam, Cambridge, UK); goat anti-BMP2/4 (Neuromics Antibodies, Edina, MN, USA); goat anti-Pdx1 (Beta Cell Biology Consortium, Nashville, TN, USA); rabbit anti-phospho-Smad2, rabbit anti-Smad2/Smad3, rabbit anti-phospho-Smad1/Smad5/Smad8 IgG (Cell Signaling Technology, Danvers, MA, USA); and mouse anti-Smad1 IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Secondary antibodies used for immunocytochemistry were Cy2-, Cy3-or Cy5-conjugated donkey anti-mouse, -rat, -rabbit or -guinea pig (Jackson ImmunoResearch, Suffolk, UK). Rat pancreatic sections were stained using peroxidase (Novared-vector, Vector Labs, Burlingame, CA, USA). Cells and sections were examined using a Zeiss LSM510 confocal microscope (Carl Zeiss, Jena, Germany).
Real-time RT-PCR Total RNA was extracted using the TRIZOL method (Invitrogen). cDNA synthesis was performed by TaqMan Gold RT-PCR kit (Perkin-Elmer, Boston, MA, USA). TaqMan gene expression probes were obtained from Applied Biosystems (Foster City, CA, USA). Each cDNA sample was subjected to two individual PCR analyses using either probes for the gene of interest or the internal control PPIA.
Insulin release and content Rat and human islets or INS1E cells were pre-incubated with BMP4 or ALK-3/Fc for 4 days before measuring glucose-and forskolin-induced insulin secretion. Insulin release from islets and INS1E cells was determined by static batch incubation or perifusion and insulin was measured as described previously [34] . One hundred islets were used per condition in the perifusion experiments and fractions were collected every 5 min. For static batch incubation, 30 islets were used per condition and insulin release was normalised to DNA content. 
Statistical analysis

Results
Regulation of beta cell proliferation by BMP4 The ability of BMP4 to regulate beta cell proliferation was studied in cultures of rat and mouse islet cells. Under basal conditions 1.4% of beta cells incorporated EdU during a 24 h labelling period. Stimulation with BMP4 for 4 days resulted in a significant reduction of beta cell proliferation with only 0.3% of beta cells showing EdU incorporation (Fig. 1a) . The inhibitory effect of BMP4 was also evident when proliferation was stimulated with beta cell growth factors (Fig. 1a) . Similar effects were observed using BMP2, which is highly homologous to BMP4 (Fig. 1b) . BMP4 inhibited proliferation of GH-stimulated beta cells in a dose-dependent manner with significant inhibition observed at 0.4 ng/ml BMP4 and maximal inhibition observed at 10 ng/ml (Fig. 1c, d ). In order to study the effect of BMP4 on adult beta cell proliferation, we cultured intact adult mouse islets in the presence of BMP4 alone or in combination with GH and glucagon-like peptide 1 (GLP-1) for 4 days. In control conditions, 1.5% of PDX-1 positive cells had incorporated EdU, which was significantly inhibited by BMP4 (Fig. 1e, f) .
To test whether the growth inhibitory effect of BMP4 was reversible, rat islet cells were stimulated with BMP4 for 4 days and subsequently cultured for an additional 4 days in the absence of BMP4. The proliferation of beta cells during the last 24 h in these cultures was similar to that seen without exposure to BMP4 (Fig. 1g) , indicating that the effect of BMP4 was reversible. To test whether inhibition of proliferation by BMP4 was associated with induction of apoptosis, we analysed islet apoptosis in response to BMP4. BMP4 did not induce apoptosis (Fig. 2a, b) whereas IL-1β, a known inducer of beta cell apoptosis, showed significant induction of apoptosis and caspase3/7 activity.
BMP signalling in beta cells
We analysed the phosphorylation of SMAD1/5/8 in response to BMP4 by western blotting. Basal SMAD1/5/8 phosphorylation could be detected in both rat and human islets. BMP4 stimulation significantly increased phosphorylation of SMAD1/5/8, whereas BMP4 did not affect the phosphorylation of SMAD2/3 ( Fig. 3a-c Figure 3d shows induction of nuclear p-SMAD1/5/8 immune-reactivity in beta cells after stimulation by BMP4.
Expression and effects of islet-derived BMP2 and -4 Expression of Bmp2/4 mRNA in islets has previously been reported, suggesting a possible auto-or paracrine effect of BMPs on beta cells. We examined the expression of BMP2 and -4 proteins by immunohistochemical staining of rat pancreas and cultured islet cells. We were unable to identify antibodies for specific identification by immunohistochemistry of BMP2 and BMP4 in paraffin-embedded tissue. Using an antibody that recognises both BMP2 and BMP4, we observed specific staining in both islet and exocrine tissue (Fig. 4a) . In cultured rat and human islet cells it was possible to obtain specific staining for BMP2 and -4. BMP2 and BMP4 expression was observed in cultures of rat and human islets (Fig. 4b, c) . BMP2 and -4 immunoreactivity was observed in beta cells as well as in non-beta cells. Also, Bmp2 and -4 mRNA could be detected in islets (see below) indicating that BMP2 and -4 are expressed and produced in islets. Since BMP2 and -4 are produced in islets, we examined the possible auto-or paracrine effects by using ALK-3 and ALK-6/Fc fusion proteins. These fusion proteins consist of the extracellular domain of BMPR1 a and b, respectively, fused to Fc and are able to neutralise BMP activity through the binding of BMP2 and -4 with high affinity. ALK-3/Fc and ALK-6/Fc fusion proteins were able to neutralise the effect of exogenous BMP4 on beta cell proliferation in a specific manner (Fig. 4d) . When islet cell cultures were incubated with ALK-3/Fc or ALK-6/Fc for 4 days, significant stimulation of basal as well as GH-stimulated beta cell proliferation was observed (Fig. 4e) Rat islet cells ) and/or BMP4 (50 ng/ml) for 72 h or (i) stimulated with a combination of IL-1β (150 pg/ml) and IFN-γ (1 ng/ml) for the indicated times. Total RNA was isolated and Bmp2 (white bars) and Bmp4 (black bars) mRNA expression was analysed using real-time PCR. Expression levels were normalised to controls (n=3). *p<0.05 vs control and † p<0.05 vs GF-stimulated islets. (j) Islets were isolated from groups of five db/db or db/+ mice at the indicated age and total RNA was isolated. Bmp2 (white bars) and Bmp4 (black bars) mRNA was analysed by realtime RT-PCR and normalised to an internal control. Results are shown as mean for two independent experiments. Data are shown as means ± SEM. FGFR4, fibroblast growth factor receptor subunit 4; GF, growth factor indicating an inhibitory activity of endogenous BMP. In addition, we found that ALK-3/Fc treatment of rat islets for 4 days inhibited the basal level of SMAD1/5/8 phosphorylation by 71%, whereas prolonged exposure to BMP4 resulted in a sustained activation of SMAD1/5/8 (Fig. 4f, g ).
Since BMP2 and -4 are produced by islets and exert growth inhibitory actions, we next examined the regulation of Bmp2 and -4 mRNA expression. The combination of beta cell growth factors (GH, GLP-1 and activin) reduced the expression of Bmp2 but not Bmp4 mRNA, while exogenous BMP4 increased the expression of both Bmp2 and -4 mRNAs (Fig. 4h) . The pro-inflammatory cytokines IL-1β and IFN-γ, known to impair beta cell growth and function, induced the expression of Bmp2 mRNA, while Bmp4 mRNA expression was not affected (Fig. 4i) . Finally, we investigated the expression of Bmp2 and -4 mRNAs in islets isolated from diabetic db/db mice. Both Bmp2 and Bmp4 mRNA expression increased with age and progression of diabetes and was 6-7 times higher in islets from 15-week-old db/db mice compared with 4-week-old mice (Fig. 4j) . In contrast, Bmp2 and -4 mRNA expression in islets from 15-week-old db/+ mice was lower than that observed in 4-week-old db/db mice and less than 10% of that seen in age-matched db/db mice.
Regulation of islet gene expression by BMP4
The family of Id genes, Id1to 4, are known downstream targets of BMPR activation [35] . Their expression in primary rat and human islets was analysed by real-time RT-PCR. In rat islets both BMP4 and BMP2 induced significant increases in Id1, -2, -3 and -4 mRNA expression (Fig. 5a) . In human islets, BMP4 induced a rapid and sustained increase (2-5 fold) in the expression of ID1, ID2, ID3 and ID4 mRNA (Fig. 5b) .
We examined the expression of p15
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Kip1 and p57 Kip2 in rat islets in response to stimulation with BMP4 and/or the combination of GH, GLP-1 and activin. Stimulation of islet cells with growth factors led to a significant decrease in the expression levels of p15, p16, p21 and p57 mRNA, which was reversed by BMP4 (Fig. 5c) .
The beta cell transcription factor paired box gene 4 (PAX4) has previously been found to induce beta cell proliferation [36] and the expression of Pax4 mRNA was significantly reduced by 50% in islets after 4 days exposure to BMP4, suggesting that the reduced expression of this transcription factor might contribute to the growth inhibitory actions of BMP4 (Fig. 5d) .
Inhibition of glucose-and forskolin-induced insulin secretion by BMP4 After 4 days of incubation with BMP4 or the BMP neutralising ALK-3/Fc fusion protein, insulin release in response to 15 mmol/l glucose and 15 mmol/l glucose plus forskolin was measured by perifusion of rat or human islets (Fig. 6a, e) . In rat islets (Fig. 6a) , BMP4 pre-treatment significantly inhibited glucose-and forskolin-stimulated insulin secretion, while pre-treatment with ALK-3/Fc enhanced forskolin-induced insulin secretion (Fig. 6b-d) . In human islets, pre-treatment with BMP4 inhibited forskolin-induced insulin secretion while ALK-3/Fc pre-treatment enhanced forskolin-induced insulin secretion (Fig. 6f, g ). Islet insulin (Fig. 6d, h ) nor did BMP4 affect the level of Ins1 or Ins2 mRNAs (Fig. 5i) . A significant reduction of insulin release at 3 mmol/l glucose was observed at 10 ng/ml and higher concentrations of BMP4, whereas inhibition by 2 ng/ml and higher concentrations of BMP4 was evident at 15 mmol/l glucose (Fig. 6j) . To test whether the inhibitory activity of BMP4 on insulin release might be dependent on other cell types present in islets, we studied the effect of BMP4 on insulin release from the clonal beta cell line INS1E. BMP4 inhibited both glucose-and forskolin-induced insulin release from INS1E cells after exposure to BMP4 (Fig. 6k) .
Discussion
The relatively scarce number of studies addressing the effects of BMP2 and -4 on regulation of postnatal beta cell mass and function stands in contrast to the extensive knowledge that exists of the critical functions that these growth factors have in the embryonic development of the pancreas [20, 37] . Expression of BMP2 and -4 is observed in postnatal mature islets [21] [22] [23] [24] . In particular, BMP2 mRNA appears to be upregulated in islets from both rodents and humans by the proinflammatory cytokines IL-1β and IFN-γ, which are known to decrease beta cell function and survival [23, 24] . Effects of BMP2 and -4 on mature beta cell function have been addressed in few studies [17, 21, 28, 38] and to our knowledge only one study has addressed the in vitro effects showing no effect on insulin secretion after 24 h exposure to BMP4 [38] . We show that Bmp2 expression is increased by inflammatory cytokines in islets, supporting previous mRNA array studies [23, 24] and that both Bmp2 and -4 mRNAs were already increased in islets at 4 weeks of age before the onset of diabetes in db/db mice. These observations are in accordance with others showing increased vascular expression of BMP2 and/or -4 in diabetic mice [16] [17] [18] [19] . We found that BMP4 inhibits beta cell proliferation and insulin secretion. The latter observation is in contrast with that found in mice with beta cell specific deletion of Bmpr1a [21] . These mice have a normal number of beta cells but altered islet alpha and beta cell distribution, and impaired glucosestimulated insulin secretion and glucose tolerance. In addition, BMP4 stimulation in vivo resulted in enhanced insulin secretion in response to glucose as well as improved glucose tolerance [21] . This was associated with a stimulatory effect of BMP4 on several beta cell genes, including the Ins gene, an effect that we do not observe after in vitro stimulation of islets with BMP4. A possible explanation for the discrepancy between our in vitro findings and those reported from genetically manipulated mice could be that the mice may have perturbed BMP signalling during embryonic development from the time of Ins or Pdx1 expression affecting the correct developmental programme for regulated insulin secretion. The presence of alpha cells scattered throughout the islets could indicate developmental effects of perturbed BMP signalling. Alternatively, we cannot exclude the possibility that some of the in vivo observations are the results of inter-organ interactions, which are not present in our islet cultures. Surprisingly, no effect was reported on the expression of Id1 mRNA in islets from mice with either inhibition or stimulation of BMP signalling [21] . In our studies BMP4 stimulates the expression of all four Id genes in cultured rat and human islet cells. Deletion of Id1 in mice was associated with enhanced beta cell function indicating that inhibitor of DNA binding 1 (ID1) is a negative regulator of insulin secretion [29] . The ID proteins are dominant negative members of the helix loop helix (HLH) family of transcription factors [39] and ID2 was able to bind and inhibit the basic HLH transcription factor NeuroD. Deletion of the NeuroD gene in beta cells results in islets with a poor response to glucose and a phenotype resembling immature beta cells [40] . BMP4-induced expression of ID proteins and subsequent inhibition of HLH transcription factors required for beta cell function might explain our observation of diminished insulin secretion in BMP4-treated islets.
Recently published studies demonstrate a positive correlation between local tissue-specific upregulation of BMP2 and/ or -4 expression and diabetes-mediated diseases including retinopathy [41] and nephropathy [42] , and vascular defects including atherosclerosis, calcification and hypertension [16, 19, 43] . Moreover, inhibition of BMP was demonstrated to have beneficial effects on these variables [16, 17, 42, 43] . A study with diabetic db/db mice further revealed that BMP inhibition not only reduced vascular inflammation but also significantly lowered blood glucose levels [17] .
In summary, our findings suggest that BMP2 and -4 negatively regulate beta cell proliferation and function. Alleviation of para-and autocrine effects of BMP2 and -4 by BMP neutralising agents such as ALK-3/Fc may represent a novel approach for protection and regeneration of adequate functional beta cell mass in diabetes.
